AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32350762
Drug: SSIDB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSIDB with 2 ml of 1% lidocaine
Trial: 32350762
Drug: SSIDB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSIDB with 1 ml of 1% lidocaine
Trial: 33903656
Drug: PAM intervention
RxNorm normalized name: 2-PAM
DrugBank: Pralidoxime (DB00733)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAM intervention as an adjunct to usual care
Trial: 33721863
Drug: Low Oral
RxNorm normalized name: Milkflow oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Oral Health Literacy (OHL) score
Trial: 36087612
Drug: PrEP adherence
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP adherence measured by plasma tenofovir concentrations of at least 40 ng/mL
Trial: 35584248
Drug: SABER-Bupivacaine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SABER-Bupivacaine 5 mL
Trial: 35584248
Drug: Placebo 5
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mL
Trial: 35584248
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrochloride 20 mL
Trial: 34405362
Drug: Streptokinase (50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (50,000 IU in 100 ml normal saline)
Trial: 34405362
Drug: 3% H2O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% H2O2 (3% H2O2 in 100 ml normal saline in 1:10 dilution)
Trial: 33686610
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg single dose with 150 mg Mg2+
Trial: 33686610
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg multiple doses with 75 mg Mg2+
Trial: 32084592
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) plus standard care (systemic anticoagulation and/or antiplatelet therapy)
Trial: 34119535
Drug: Ranibizumab 100
RxNorm normalized name: ranibizumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 100 μg/ml
Trial: 34119535
Drug: Aflibercept 400
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept 400 μg/ml
Trial: 34119535
Drug: Conbercept 100
RxNorm normalized name: Conbercept
DrugBank: Conbercept (DB12460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conbercept 100 μg/ml
Trial: 34119535
Drug: 3‐MA or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐MA or CQ (autophagy inhibitors)
Trial: 32521132
Drug: Givosiran (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givosiran (2.5 mg/kg, subcutaneous, monthly for 6 months)
Trial: 34845313
Drug: 100 µg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg of vitamin K2 (MK‐7)
Trial: 34845313
Drug: 10 µg of
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 µg of native vitamin D
Trial: 34845313
Drug: 100 µg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg of vitamin K2 (MK‐7) and 10 µg of native vitamin D
Trial: 33686887
Drug: SilvrSTAT Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SilvrSTAT Gel dressing
Trial: 32326757
Drug: Modified relative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified relative dose response (MRDR) test
Trial: 33248910
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration nano-hydroxyapatite (nHAP) applied for 2 to 3 minutes daily for 10 days
Trial: 32816944
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg infusion with cisplatin and gemcitabine
Trial: 32816944
Drug: Bevacizumab 2.5
RxNorm normalized name: Bevacizumab 2.5 MG/0.1 ML Intraocular Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 2.5 mg/kg infusion with cisplatin and gemcitabine
Trial: 32816944
Drug: Sunitinib 12.5
RxNorm normalized name: sunitinib 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 12.5 mg/day with cisplatin and gemcitabine
Trial: 32816944
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg/day with cisplatin and gemcitabine
Trial: 32816944
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and gemcitabine chemotherapy without anti-VEGF therapy
Trial: 35242594
Drug: Blended cognitive-behavioral
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended cognitive-behavioral therapy (CBT)
Trial: 35242594
Drug: Standard cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive-behavioral therapy (CBT)
Trial: 35157993
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment after relapse
Trial: 33838224
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus TPE (n=43)
Trial: 33838224
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n=44)
Trial: 32687161
Drug: RTS,S/AS01B or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01B or RTS,S/AS01E (3 doses on a 0-1-7-month schedule, with the final 1 or 2 doses being fractional)
Trial: 32687161
Drug: RTS,S/AS01E (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E (2 doses: 1 full at month 0 and 1 fractional at month 7)
Trial: 33151132
Drug: Saffron group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron group (received routine care plus capsule of saffron 400 mg/day, 200 mg twice per day)
Trial: 34259401
Drug: Estazolam tablets
RxNorm normalized name: Estazolam Tablets
DrugBank: Estazolam (DB01215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estazolam tablets (1 mg)
Trial: 32255785
Drug: PBM in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM in the sublingual region
Trial: 35237033
Drug: Liraglutide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3.0 mg, s.c.)
Trial: 32331064
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg SPN-812
Trial: 33836772
Drug: Mass Screening
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Screening and Treatment (MST) intervention
Trial: 34085115
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg/day)
Trial: 36093566
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg selenium as selenium-enriched yeast daily
Trial: 36093566
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg selenium as selenium-enriched yeast daily
Trial: 36093566
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg selenium as selenium-enriched yeast daily
Trial: 36093566
Drug: 100, 200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100, 200, or 300 μg selenium as selenium-enriched yeast daily
Trial: 33609973
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) in high-risk patients (34.4%, n = 166)
Trial: 33609973
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) in low-risk patients (36.5%, n = 203)
Trial: 36145126
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B1 and mecobalamin, artificial tears
Trial: 33351971
Drug: HTL0018318 (1–35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0018318 (1–35 mg)
Trial: 32275025
Drug: Propofol-dexmedetomidine continuous
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-dexmedetomidine continuous infusion
Trial: 32275025
Drug: Propofol continuous
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol continuous infusion
Trial: 32359348
Drug: Butorphanol at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol at the ED95 dose (9.07 μg/kg)
Trial: 32359348
Drug: Sufentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil at the ED95 dose (0.1 μg/kg)
Trial: 35230488
Drug: delgocitinib ointment
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: delgocitinib ointment 30 mg/g (n = 20)
Trial: 35230488
Drug: vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle ointment (n = 11)
Trial: 33352007
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program combined with manual therapy (mobilization group)
Trial: 33352007
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy only (control group)
Trial: 35690093
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose injection
Trial: 35690093
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% sodium chloride) injection
Trial: 36123185
Drug: Freehand group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freehand group (screw channel preparation based on panoramic radiographs without a drilling guide)
Trial: 34045114
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion policy (packed cells when Hemoglobin < 8 g/dL)
Trial: 34045114
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion policy (packed cells when Hemoglobin < 10 g/dL)
Trial: 35413602
Drug: Pequi oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pequi oil nanoencapsulated gel (PeONC)
Trial: 35749267
Drug: MAX intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAX intervention (problem-solving therapy with energy conservation education)
Trial: 33415866
Drug: Moxibustion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion therapy (once daily for 14 days)
Trial: 33415866
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (western medicine)
Trial: 34954870
Drug: Digital informed
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital informed consent (DIC) using hyperrealistic simulation on a tablet device
Trial: 36167477
Drug: Ropivacaine 0.375%
RxNorm normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.375% 30 mL on each side
Trial: 33393805
Drug: Cue detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue detection and combination conditions
Trial: 36207643
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered through a target-controlled infusion device programmed with the covariates model, plasma target concentrations between 2 and 5 μg.mL−1.
Trial: 34533825
Drug: 20 opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 opioid pills (Group 1)
Trial: 34533825
Drug: 40 opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 opioid pills (Group 2)
Trial: 33039944
Drug: Ocrelizumab 600
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 600 mg administered over 3.5 hours (conventional duration)
Trial: 33039944
Drug: Ocrelizumab 600
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 600 mg administered over 2 hours (shorter duration)
Trial: 33963479
Drug: β ‐glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β ‐glucan (200 mg daily)
Trial: 33675850
Drug: Methotrexate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (25 mg weekly oral)
Trial: 33675850
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil (1.5 g twice daily oral)
Trial: 32651955
Drug: PT20 (400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT20 (400, 800, 1600 or 3200 mg)
Trial: 39577033
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment
Trial: 32093617
Drug: Sumatriptan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (4 mg)
Trial: 32556659
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + nutraceutical agent (test group)
Trial: 34459089
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural intervention (CBT) with compassion-focused therapy methods, delivered in six sessions.
Trial: 33077017
Drug: 3% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hypertonic saline (HYPER) infusion (0.1 ml/kg per min for 2 hours)
Trial: 33964853
Drug: Wolfberry (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wolfberry (15 g/d)
Trial: 33469316
Drug: Tezepelumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (all doses)
Trial: 36216004
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet of less than 1500 mg/day
Trial: 33932589
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg, intravenously, Q 12 h) for the first 5 postoperative days
Trial: 33932589
Drug: On-demand opioid
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand opioid analgesics (pethidine or morphine) postoperatively
Trial: 35829974
Drug: Delicate pulsed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delicate pulsed light (DPL) combined with low-dose oral isotretinoin (10–20 mg/day)
Trial: 35829974
Drug: Isotretinoin monotherapy
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin monotherapy
Trial: 33742786
Drug: HBM9161 340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 340 mg
Trial: 33742786
Drug: HBM9161 510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 510 mg
Trial: 33742786
Drug: HBM9161 680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 680 mg
Trial: 35783528
Drug: Xinjia Xuanbai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinjia Xuanbai Chengqi granules (XJXBCQ) combined with conventional treatment (budesonide suspension)
Trial: 35783528
Drug: Xinjia Xuanbai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinjia Xuanbai Chengqi granules (XJXBCQ) and budesonide suspension (full dosage)
Trial: 35783528
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (budesonide suspension and placebo)
Trial: 32914639
Drug: Enhanced upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced upper limb therapy programme (36 one-hour sessions over 12 weeks, including 45 minutes of face-to-face therapy)
Trial: 32434291
Drug: Nebulized dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized dexmedetomidine (1 µg/kg in 3‐4 ml of 0.9% saline)
Trial: 32434291
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (3‐4 ml)
Trial: 35065683
Drug: High-titre RV3-BB
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-titre RV3-BB vaccine
Trial: 35065683
Drug: Mid-titre RV3-BB
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mid-titre RV3-BB vaccine
Trial: 35065683
Drug: Low-titre RV3-BB
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-titre RV3-BB vaccine
Trial: 35065683
Drug: High-titre RV3-BB
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-titre RV3-BB vaccine (infant schedule)
Trial: 35065683
Drug: Overall vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall vaccine take
Trial: 33423986
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (10 mg/kg in 100 ml isotonic saline)
Trial: 33423986
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 ml isotonic saline)
Trial: 34520052
Drug: Anti-PD-1-based first-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-PD-1-based first-line treatment
Trial: 35157236
Drug: HSK3486 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 0.4 mg/kg
Trial: 33100184
Drug: Contact-control intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact-control intervention (CC)
Trial: 33746195
Drug: Papilocare, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papilocare, a Coriolus versicolor-based vaginal gel
Trial: 35170523
Drug: Parent-reported use
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-reported use of topical corticosteroids
Trial: 35710091
Drug: Calf muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf muscle exercise training (ETC) in addition to compression therapy (CT)
Trial: 35710091
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (IMT) in addition to compression therapy (CT)
Trial: 33957371
Drug: Rasburicase 1.5
RxNorm normalized name: rasburicase 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasburicase 1.5 mg
Trial: 33957371
Drug: Rasburicase 3
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rasburicase 3 mg
Trial: 33957371
Drug: Rasburicase (1.5−3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasburicase (1.5−3 mg) with allopurinol 300 mg daily
Trial: 34260549
Drug: Group Rational
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Rational Emotive Behavior Therapy (group REBT)
Trial: 32213019
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for acute and chronic pouchitis
Trial: 33612439
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (16 g/d)
Trial: 33612439
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplementation (16 g/d)
Trial: 33612439
Drug: Whey-soy blended
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey-soy blended protein supplementation (16 g/d)
Trial: 36277594
Drug: Sequential ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential ventilation therapy
Trial: 33902955
Drug: Chemotherapy (vinflunine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or docetaxel 75 mg/m2 according to investigator choice) every 3 weeks
Trial: 34195784
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia alone with postoperative intravenous analgesia
Trial: 35780458
Drug: Health care
RxNorm normalized name: Health Care Lancing Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health care worker training intervention (SISTAQUIT) including ABCD approach, educational resource package, free oral nicotine replacement therapy, implementation support, and trial implementation training
Trial: 32703215
Drug: Health worker
RxNorm normalized name: Apis cerana worker secretion preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health worker knowledge of artesunate treatment policies